Posted by Michael Wonder on 04 Jan 2023
Samsung Bioepis announces Health Canada approval of citrate free high concentration of Humira biosimilar (adalimumab; SB5)
3 January 2023 - With the approval, Samsung Bioepis has both low (40 mg/0.8 mL) and high (40 mg/0.4 mL) concentration of adalimumab biosimilar approved in Canada.
Samsung Bioepis today announced that Health Canada has approved Hadlima (also known as SB5) - a citrate free, high concentration (40 mg/0.4 mL) formulation of biosimilar referencing Humira (adalimumab).
